Escitalopram in Patients With Social Anxiety Disorder

Official Title: “Efficacy and Safety of Escitalopram in Patients With Social Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia”

The purpose of this study is to evaluate the effect of escitalopram after 12 weeks of treatment in patients with Social Anxiety Disorder (SAD), to evaluate proportion of patients who respond to escitalopram during the treatment period, and to evaluate safety of escitalopram.

The study will be performed in Russia, as an open-label, uncontrolled, one arm trial. The patients will receive escitalopram for 12 weeks. Start and maintenance dosages as well as dose titration will be left to the investigators' decision (5 to 20 mg/day), in accordance with the national Summary of Products Characteristics (SPC).

Intervention(s) in this Clinical Trial

• Drug: Escitalopram
  • Flexible-dosed (5 to 20 mg Oral Tablets Daily)

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: Escitalopram

Primary Measures

• Effect of Escitalopram After 12 Weeks Using the Clinical Global Impression (CGI-I)
  • Time Frame: baseline and 12 weeks
    Safety Issue?: No

Secondary Measures

• Effect of Escitalopram After 12 Weeks Using the Clinical Global Impression (CGI-S)
  • Time Frame: baseline and 12 weeks
    Safety Issue?: No
• Percentage of Patients Who Responded to Escitalopram After 12 Weeks of Treatment Using CGI-I <= 2
  • Time Frame: baseline and 12 weeks
    Safety Issue?: No
• Percentage of Patients Who Achieved Remission After 12 Weeks of Treatment Using CGI-S <= 2
  • Time Frame: baseline and 12 weeks
    Safety Issue?: No
• Effect of Escitalopram After 12 Weeks Using Sheehan Disability Scale (SDS) Work
  • Time Frame: baseline and 12 weeks
    Safety Issue?: No
• Effect of Escitalopram After 12 Weeks Using Sheehan Disability Scale (SDS) Family
  • Time Frame: baseline and 12 weeks
    Safety Issue?: No
• Effect of Escitalopram After 12 Weeks Using Sheehan Disability Scale (SDS) Social
  • Time Frame: baseline and 12 weeks
    Safety Issue?: No

Inclusion Criteria:

• The patient suffers from SAD, diagnosed according to ICD-10 (International
• Classification of Diseases)
• The patient meets criteria set in the national SPC for escitalopram
• The patient is, in the opinion of the investigator, otherwise healthy on the basis of a physical examination, medical history and vital signs

Exclusion Criteria:

• The patient has/has had an alcohol or drug abuse-related disorder, as defined in ICD-10
• The patient has contraindications to escitalopram
• The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to escitalopram
• The patient has a serious illness and/or serious sequelae thereof, including liver or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbance
• The patient is pregnant or breast-feeding
• The patient, if a woman of childbearing potential, is not using adequate contraception

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 65 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: H. Lundbeck A/S Industry

Overall Clinical Trial Officials and Contacts

Email contact viaH. Lundbeck A/S viaH. Lundbeck A/S Study Director LundbeckClinicalTrials@lundbeck.com  

Information obtained from ClinicalTrials.gov on February 08, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00902226

Study ID Number: 12133A

ClinicalTrials.gov Identifier: NCT00902226

Health Authority: Russia: Ministry of Health and Social Development of the Russian Federation